Skip to main content

CNCR - Loncar Cancer Immunotherapy ETF


CNCR - Loncar Cancer Immunotherapy ETF

CNCR takes an approach to niche coverage within the health care sector. It provides equal-weighted exposure to about 30 companies of various sizes that have approved immunotherapy cancer drugs on the US or European markets or that are engaged in human clinical trials of such drugs. The fund seeks a holistic exposure to the immunotherapy space, specifically including companies with varying drug mechanisms. Equal-weighting of the securities draws attention to smaller companies with room to grow. This fund provides a unique option for investors placing a highly specialized bet on this space.